Company intelligence / Profile preview
ImmuneCyte Life Sciences
California, United States
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Clinical-stage biopharmaceutical company developing cell and gene therapeutics, including CAR-T and antibody therapies, primarily for cancer and other diseases. Acquired IP for COVID-19 monoclonal antibodies in 2020.
- Therapeutic areas
- Women's HealthCardiovascularInfectious DiseasesRheumatologyRare DiseasesOncology
- Modalities
- Cell therapyT-lymphocyte cell therapyCAR-TMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
Request access →03
Partnerships
ThermoGenesis Holdings, Inc. (joint venture partner, ~19% ownership)East China Normal University (IP acquisition source)
Beyond the preview
Go deeper on ImmuneCyte Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmuneCyte Life Sciences.